PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UK
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.776
https://www.valueinhealthjournal.com/article/S1098-3015(18)34076-2/fulltext
Title :
PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34076-2&doi=10.1016/j.jval.2018.09.776
First page :
Section Title :
Open access? :
No
Section Order :
179